Journal
NEUROSCIENCE BULLETIN
Volume 30, Issue 2, Pages 295-307Publisher
SPRINGER
DOI: 10.1007/s12264-013-1406-z
Keywords
agonist; Alzheimer's disease; amyloid; cholinergic hypofunction; M1 muscarinic acetylcholine receptor; tau
Categories
Funding
- National Institutes of Health, USA [R01AG038710, R01AG021173, R01AG044420, R01NS046673]
- Alzheimer's Association
- National Natural Science Foundation of China [91332112, 81225008, 81161120496]
- Fundamental Research Funds for the Central Universities of China
- Fok Ying Tung Education Foundation
Ask authors/readers for more resources
The degeneration of cholinergic neurons and cholinergic hypofunction are pathologies associated with Alzheimer's disease (AD). Muscarinic acetylcholine receptors (mAChRs) mediate acetylcholine-induced neurotransmission and five mAChR subtypes (M1-M5) have been identified. Among them, M1 mAChR is widely expressed in the central nervous system and has been implicated in many physiological and pathological brain functions. In addition, M1 mAChR is postulated to be an important therapeutic target for AD and several other neurodegenerative diseases. In this article, we review recent progress in understanding the functional involvement of M1 mAChR in AD pathology and in developing M1 mAChR agonists for AD treatment.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
